长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效及生存因素分析

目的分析长春瑞滨(navelbine,NVB)联合顺铂(cisplatin)治疗晚期非小细胞肺癌(non-smallcell lung cancer,NSCLC)患者的临床疗效及预后相关性生存因素。方法 59例经病理或细胞学证实的Ⅲb一Ⅳ期晚期NSCLC患者均接受长春瑞滨联合顺铂(NP)治疗方案,服药前及服药后每2～3周进行疗效及全身评估。结果 59例NSCLC患者完全缓解1例(1.95%)、部分缓解21例(35.59%)、稳定15例(25.42%)、进展22例(37.29%),总有效率37.29%。中位总生存期14.9个月,无治疗相关性死亡。结论 NVB联合顺铂对晚期非小细胞肺癌有较好临床疗效,和患者的预后相关性生存因素密切相关。NVB联合顺铂可作为晚期NSCLC的较有效治疗方案。

Efficacy of navelbine and cisplatin chemotheraphy on advanced non-small cell lung cancer and analysis of survival associated factors

Objective To evaluate the efficacy of navelbine and cisplatin chemotheraphy on advanced non-small cell lung cancer and analysis of survival associated factors. Methods A total of 59 cases of stage Ⅲb-Ⅳ NSCLC confirmed by pathological and cytological examination were accepted chemotheraphy of navelbine and cisplatin in this study, we evaluagted the efficacy and whole body condition before and every 2-3 weeks after administration of erlotinib. Results 59 cases of patients with NSCLC completely eatabatic were 1 cases （ 1.95% ） , part catabatic were 21 cases （35.59%）, stable 15 cases （25.42%）, and progress 22 cases （37.29%）, the total effective rate was 37.29%. The median survival time was 14.9 months and no treatment-related deaths. Conclusions The chemotheraphy of navelbine and cisplatin for stage advanced non-small cell lung cancer has good clinical curative effect, and the prognosis of patients with correlation survival factors are closely related. The chemotheraphy of navelbine and cisplatin as advanced-stage NSCLC did more effective treatments.